Clinical Scorecard: EYP-1901 Shows Durable, Sustained Efficacy in VERONA
At a Glance
| Category | Detail |
|---|---|
| Condition | Diabetic Macular Edema (DME) |
| Key Mechanisms | EYP-1901 is a potent tyrosine kinase inhibitor (TKI) combined with a bioerodible polymer for sustained drug delivery. |
| Target Population | Patients with center-involved DME and decreased visual acuity. |
| Care Setting | Multicenter clinical trial |
Key Highlights
- EYP-1901 showed a greater percentage of patients supplement-free at week 24 (73% high dose, 60% low dose) compared to aflibercept (50%).
- Significant improvement in best-corrected visual acuity (BCVA) observed as early as week 4.
- 40% to 50% of patients in EYP-1901 arms were free of DME at week 24, compared to 0% in the aflibercept arm.
- EYP-1901 demonstrated excellent safety with no serious adverse events reported.
- The study met its primary endpoint of time to supplemental anti-VEGF injection.
Guideline-Based Recommendations
Diagnosis
- Diagnosis of DME should include assessment of visual acuity and optical coherence tomography (OCT).
Management
- EYP-1901 is recommended for patients with center-involved DME, showing superior efficacy compared to aflibercept.
Monitoring & Follow-up
- Monitor visual acuity and CST at regular intervals post-injection.
Risks
- No EYP-1901–related serious adverse events or systemic adverse events were reported.
Patient & Prescribing Data
Patients with center-involved DME and decreased visual acuity.
EYP-1901 provides sustained anti-VEGF activity with a favorable safety profile.
Clinical Best Practices
- Consider EYP-1901 for patients requiring long-term management of DME.
- Utilize OCT and visual acuity assessments to guide treatment decisions.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.